Medical Specialty Hub
Cancer Immunotherapy: Mechanisms, Checkpoints & Cellular Therapies
A comprehensive clinical guide to immuno-oncology, immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4), adoptive CAR-T cell therapy, predictive biomarkers, and adverse event management.
25+
FDA Approved Indications
6
Approved CAR-T Products
3
Key Predictive Biomarkers
2,000+
Global Clinical Trials
How Immuno-Oncology Works
Cancer cells exploit physiological immunosuppressive pathways known as "immune checkpoints" to evade cytotoxic T-cell detection and destruction. Under normal physiological conditions, these checkpoints (such as Programmed Death-1 [PD-1] and Cytotoxic T-Lymphocyte-Associated Protein 4 [CTLA-4]) maintain self-tolerance and protect tissues from autoimmune damage.
By binding to PD-1 on T-lymphocytes, tumor cells expressing the ligand PD-L1 transmit inhibitory signals that induce T-cell exhaustion and anergy. Immune checkpoint inhibitor therapies selectively interrupt these receptor-ligand interactions, restoring antineoplastic cellular immunity and fostering durable clinical remissions.
Predictive Biomarkers for Immunotherapy Response
Identifying patients who will derive maximum therapeutic benefit while avoiding unnecessary immune toxicities:
| Biomarker |
Evaluation Metric |
Clinical Interpretation |
| PD-L1 Expression |
TPS (Tumor Proportion Score) & CPS (Combined Positive Score) |
Higher expression predicts elevated probability of response in NSCLC, gastric, cervical, and TNBC. |
| MSI-H / dMMR |
IHC (MLH1, MSH2, MSH6, PMS2) & PCR / NGS |
Tissue-agnostic FDA approval for Pembrolizumab and Dostarlimab across any solid tumor with mismatch repair deficiency. |
| Tumor Mutational Burden (TMB) |
NGS (≥ 10 mutations/megabase) |
Generates high loads of neoantigens, prompting robust recognition by the patient's adaptive immune system. |
Managing Immune-Related Adverse Events (irAEs)
By removing negative immune regulators, checkpoint blockade can trigger autoimmune inflammation affecting any organ system:
- Colitis & Enteritis: Characterized by persistent diarrhea and abdominal pain; managed with high-dose corticosteroids or infliximab.
- Pneumonitis: Non-infectious lung inflammation requiring immediate oxygen assessment, radiographic HRCT evaluation, and prompt steroid administration.
- Endocrinopathies: Hypophysitis, hypothyroidism, and adrenal insufficiency, frequently requiring permanent hormone replacement therapy.
- Hepatitis: Asymptomatic elevation in AST/ALT requiring routine liver function monitoring before each infusion cycle.
Frequently Asked Questions (Clinical FAQ)
Chemotherapy targets rapidly dividing cells indiscriminately. Immunotherapy works by training or liberating the body's own immune system to specifically identify, infiltrate, and eliminate tumor cells, often yielding long-lasting immune memory and durable responses.
They are monoclonal antibodies that block molecules like PD-1, PD-L1, or CTLA-4. When cancer cells engage these receptors, they shut down cytotoxic T-cells. Inhibitors break this molecular handshake, empowering T-cells to attack the malignancy.
The standard clinical biomarkers are PD-L1 expression levels (TPS and CPS scores), Microsatellite Instability High (MSI-H) / Deficient Mismatch Repair (dMMR), and high Tumor Mutational Burden (TMB-H ≥ 10 mut/Mb).
irAEs are inflammatory autoimmune complications resulting from an overstimulated immune system. They can affect the gastrointestinal tract (colitis), lungs (pneumonitis), liver (hepatitis), and endocrine glands. Most cases are reversible when treated promptly with systemic corticosteroids.
CAR-T therapy involves leukapheresis to harvest the patient's T-cells, viral vector transduction in a laboratory to introduce a tumor-targeting Chimeric Antigen Receptor, ex vivo expansion, and re-infusion back into the patient after lymphodepleting conditioning chemotherapy.
